Aliases for ABCB1 Gene
External Ids for ABCB1 Gene
Previous HGNC Symbols for ABCB1 Gene
Previous GeneCards Identifiers for ABCB1 Gene
The membrane-associated protein encoded by this gene is a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This protein is a member of the MDR/TAP subfamily. Members of the MDR/TAP subfamily are involved in multidrug resistance. The protein encoded by this gene is an ATP-dependent drug efflux pump for xenobiotic compounds with broad substrate specificity. It is responsible for decreased drug accumulation in multidrug-resistant cells and often mediates the development of resistance to anticancer drugs. This protein also functions as a transporter in the blood-brain barrier. [provided by RefSeq, Jul 2008]
GeneCards Summary for ABCB1 Gene
ABCB1 (ATP-Binding Cassette, Sub-Family B (MDR/TAP), Member 1) is a Protein Coding gene. Diseases associated with ABCB1 include colchicine resistance and inflammatory bowel disease 13. Among its related pathways are MicroRNAs in cancer and Integrated Pancreatic Cancer Pathway. GO annotations related to this gene include transporter activity and xenobiotic-transporting ATPase activity. An important paralog of this gene is ABCB11.
UniProtKB/Swiss-Prot for ABCB1 Gene
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells
P-glycoprotein (ABCB1, MDR1) is a well-characterized human ABC transporter that was the first ABC transporter implicated in multidrug resistance. Normal physiological expression of P-glycoprotein has been found to prevent uptake of some lipophilic drugs into the brain and other key organs. P-glycoprotein is frequently overexpressed in cancer cells resulting in drugs being pumped out of the cells faster than they can enter. This causes a lower concentration of the drug in the cell and reduces the effectiveness of the drugs in killing cancer cells. Drugs that are affected by classical multidrug resistance include the vinca alkaloids (vinblastine and vincristine), the anthracyclines (doxorubicin and daunorubicin), the RNA transcription inhibitor actinomycin D and the microtubule-stabilizing drug taxol.